WILL GLPS REQUIRE AN ADD-ON BONE DRUG?
MORE SIDE EFFECTS EMERGE WITH BLOCKBUSTER DRUG
By MARTHA ROSENBERG
As industry watchers predicted, long-term effects of GLP-1 agonists are squelching market inebriation— like hair and muscle loss effects, and now bone loss.
“ Any medication that sees this rapid adoption warrants close examination, particularly in orthopaedics where obesity and surgical intervention often overlap,” said Muaaz Wajahahth, presenting a paper about the weight loss drugs’ links to bone risks at the annual meeting of the American Academy of Orthopaedic Surgeons in New Orleans in March.
“ We are just now reaching the precipice where five- and 10-year follow-up data are becoming available for patients taking GLP-1 medications,” said Wajahahth.
Already, pharma start-ups are marketing drugs to address
GLP muscle loss and eye harm as plastic surgeons clean up on“ Ozempic faces.” Will add-on bone drugs be next?
Bones Have Been A Serious Breaking Point For Drugmakers
Bones have been a serious breaking point, pun intended, for drugmakers / sellers since hormone replacement therapy( HRT) crashed and burned over 20 years ago. Why?
When the federally funded Women’ s Health Initiative( WWI) concluded that HRT increased the risk of breast cancer by 26 percent, heart attacks by 29 percent, stroke by 41 percent and doubled the risk of blood clots, drugmakers desperately tried to retain their revenue by marketing
The Trial Lawyer 93